Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure

Executive Summary

The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.

You may also be interested in...

Gottlieb Adds A No. 2: Sherman Is US FDA Principal Deputy Commissioner

Rachel Sherman takes over a position that has not been filled permanently since Josh Sharfstein left in 2011.

Sharfstein On Zohydro: FDA Should Require Opioid Abuse Deterrent Standards

Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.

FDA Reorganization Will Not Include John Taylor As Top Aide To Commissioner

John Taylor’s exit from the agency comes as FDA Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure the centers support Office of Regulatory Affairs’ activities without duplication.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts